Showing results (1551-1560 of 1,579) with videos related to
Sort By:
Pageof 158
Cell Metabolism|May 1, 2018
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human PrimatesDavid G McLaren, Seongah Han, Beth Ann Murphy, et al.Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole coreDong-Ming Shen, Edward J Brady, Mari R Candelore, et al.Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.Epilepsia|July 9, 2025
Variants in CSMD2 and CSMD3, genes involved in synaptogenesis, are associated with epilepsiesXiang Li, Lin Wang, Xiao-Yu Liang, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.Bioorganic & Medicinal Chemistry Letters|August 17, 2005
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonistsDong-Ming Shen, Fengqi Zhang, Edward J Brady, et al.Cell Research|January 6, 2026
Sensing of DNA double-strand breaks by the NHEJ system stabilizes RORγt transcriptional activity and shapes Th17 pathogenicity in autoimmunityGuan-Yu Chen, Wen-Jie Zhu, Zhuang Li, et al.Journal of Medicinal Chemistry|March 3, 2017
Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 InhibitorsTim Cernak, Nathan J Gesmundo, Kevin Dykstra, et al.Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.Journal of Medicinal Chemistry|March 4, 2025
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome InhibitorDong-Ming Shen, Kate F Byth, Damien Bertheloot, et al.Pageof 158